The Pharmaceutical Journal
Vol 278 No 7448 p450
21 April 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Rapid genotyping assay could simplify warfarin dose choice

Genotypes affecting the dose-response to warfarin can be accurately detected with a rapid genotyping assay that could simplify dosage decisions, according to data reported at the American College of Cardiology 2007 Scientific Sessions held in New Orleans last month.

The trial tested a rapid genotyping method, based on the finding that variability in patient response to warfarin is caused, in part, by variations in the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genes.

Patients’ DNA was extracted from buccal swabs and a polymerase chain reaction was used to amplify it for the VKORC1 and CYP2C9*2 and *3 polymorphisms. The one-hour test means that results can guide optimal warfarin dosing without delaying initiation of therapy.